Abstract:Background:Only about half of patients with type 2 diabetes treated with antihyperglycemic drugs achieve glycemic control (HbA1c <7%), most commonly due to poor treatment adherence. Glucagon-like peptide-1 (GLP-1) receptor agonists act on multiple targets involved in glucose homeostasis and have a low risk of causing hypoglycemia. While GLP-1 receptor (GLP-1R) agonists share the same mechanism of action, clinical profiles of individual agents differ, particularly between short- and long-acting agents. In this article, recent findings regarding the pharmacology of GLP-1 agonists are reviewed, and the clinical effects of short- versus long-acting agents are compared.Data sources:Relevant articles were identified through a search of PubMed using the keywords glucagon-like peptide-1, GLP-1, glucagon-like peptide-1 receptor agonist, GLP-1R agonist, and exenatide for publications up to 22 May 2015. Supporting data were obtained from additional searches for albiglutide, dulaglutide, liraglutide and lixisenatide as well as from the bibliographies of key articles.Findings:Short-acting GLP-1R agonists produce greater reductions in postprandial glucose levels by slowing gastric emptying, whereas long-acting GLP-1R agonists produce greater reductions in fasting blood glucose by stimulating insulin secretion from the pancreas. These characteristics can be exploited to provide individualized treatment to patients. A large body of evidence supports the benefits of short- and long-acting exenatide as add-on therapy in patients with inadequate glycemic control despite maximum tolerated doses of metformin and/or sulfonylurea. Exenatide is generally well tolerated and no new safety concerns were identified during long-term follow-up of up to 5 years. A limitation of this review of short-and long-acting GLP-1 receptor agonists is that it focuses on exenatide rather than all the drugs in this class. However, the focus on a single molecule helps to avoid any confusion that may be introduced as a result of differences in molecular structure and size.Conclusions:Short-acting GLP-1R agonists including exenatide are well suited to patients with type 2 diabetes with exaggerated postprandial glucose excursions and for co-administration with basal insulin therapy. Long-acting GLP-1R agonists including once weekly exenatide offer greater convenience and are well suited to patients who require specific control of fasting hyperglycemia.

Antidiabetic Drugs and Exenatide

Recent Development of Exendin-4 and Its Analogs

The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus

The Value of Short- and Long-Acting Glucagon-Like Peptide-1 Agonists in the Management of Type 2 Diabetes Mellitus: Experience with Exenatide

The clinical experience of GLP-1 receptor agonist drugs

Opportunities and Challenges of Incretin-Based Hypoglycemic Agents Treating Type 2 Diabetes Mellitus from the Perspective of Physiological Disposition

Drug Discovery Approaches Targeting the Incretin Pathway

Novel DPP-4 Inhibitors Against Diabetes

Pharmacokinetic/pharmacodynamic Studies on Exenatide in Diabetic Rats

Progress on Glucosidase Inhibitors

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs

Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.

Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation

Review on pharmacokinetic/pharmacodynamic models of the related agents of incretin

Effects of Exenatide on Lipid Metabolism of Adipose Tissue in Diabetic Rats

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

The Cardiovascular Effect of Glucagon-like Peptide-1 Receptor Agonists

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management

New Hypoglycemic Drugs: Combination Drugs and Targets Discovery